Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Review: implants

P Ashton1, D L Blandford, P A Pearson

  • 1Department of Ophthalmology, Kentucky Clinic, University of Kentucky, Lexington.

Journal of Ocular Pharmacology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cryogenic continuously rotating half-wave plate mechanism for the POLARBEAR-2b cosmic microwave background receiver.

The Review of scientific instruments·2020
Same author

A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients.

Bone marrow transplantation·2017
Same author

Recognition and Prevention of Rugby Injuries.

The Physician and sportsmedicine·2016
Same author

Anterior Tibial Pain in a Baseball Player.

The Physician and sportsmedicine·2016
Same author

Association between use of proton pump inhibitors and non-typhoidal salmonellosis identified following investigation into an outbreak of Salmonella Mikawasima in the UK, 2013.

Epidemiology and infection·2015
Same author

Absorbable laparoscopic ligating clips: Impact on postoperative CT imaging.

Clinical radiology·2014
Same journal

Systemic delivery of polypeptide drugs through ocular route.

Journal of ocular pharmacology·1994
Same journal

Mucoadhesive ophthalmic vehicles: evaluation of polymeric low-viscosity formulations.

Journal of ocular pharmacology·1994
Same journal

The role of iontophoresis in ocular drug delivery.

Journal of ocular pharmacology·1994
Same journal

Ion exchange resins for ophthalmic delivery.

Journal of ocular pharmacology·1994
Same journal

In situ-forming gels for ophthalmic drug delivery.

Journal of ocular pharmacology·1994
Same journal

A rationale for gene targeting in glaucoma therapy.

Journal of ocular pharmacology·1994
See all related articles

New implantable devices offer sustained drug delivery for chronic eye conditions like CMV retinitis and uveitis, potentially improving treatment control and reducing side effects.

Area of Science:

  • Ophthalmology
  • Biomaterials Science
  • Drug Delivery Systems

Background:

  • Chronic ocular disorders require long-term therapeutic interventions.
  • Current treatments for conditions like cytomegalovirus (CMV) retinitis and uveitis often involve frequent administration and can have significant side effects.
  • There is a need for advanced drug delivery systems to provide sustained and localized treatment within the eye.

Purpose of the Study:

  • To develop and evaluate an implantable sustained-release device for chronic eye disease treatment.
  • To assess the efficacy and duration of drug delivery for ganciclovir and cyclosporine A implants.
  • To investigate the potential of subconjunctival implants for maintaining ocular health.

Main Methods:

  • Development of a multi-layered implantable device with a drug core encased in permeable and impermeable polymers.

Related Experiment Videos

  • Subconjunctival or intravitreal implantation of devices loaded with ganciclovir for CMV retinitis and cyclosporine A for uveitis.
  • Monitoring of drug levels in the vitreous and assessment of therapeutic outcomes and intraocular pressure.

    • Main Results:

    • Ganciclovir implants maintained therapeutic vitreous drug levels for 8 months in patients with CMV retinitis, showing potential for better disease control and fewer side effects.
    • Cyclosporine A implants demonstrated sustained therapeutic vitreous levels for approximately 3 years in uveitis treatment studies.
    • Subconjunctival 5-fluorouracil (5-FU) implants maintained ocular filters in monkeys for 3 months and helped lower intraocular pressure in high-risk patients.

    Conclusions:

    • Implantable sustained-release devices offer a promising approach for managing chronic ocular diseases.
    • These devices can provide long-term, localized drug delivery, potentially improving patient outcomes and reducing systemic side effects.
    • Further research is ongoing to evaluate the full efficacy and toxicity profile of these novel ocular drug delivery systems.